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ABSTRACT  
Pulmonary delivery of protein therapeutics has considerable clinical potential for treating both 
local and systemic diseases. However, poor protein conformational stability, immunogenicity 
and protein degradation by proteolytic enzymes in the lung are major challenges to overcome 
for the development of effective therapeutics. To address these, a family of structurally related 
copolymers comprising polyethylene glycol, mPEG2k, and poly(glutamic acid) with linear A-
B (mPEG2k-lin-GA) and miktoarm A-B3 (mPEG2k-mik-(GA)3) macromolecular architectures 
was investigated as potential protein stabilisers. These copolymers form non-covalent 
nanocomplexes with a model protein (lysozyme) which can be formulated into dry powders by 
spray-drying using common aerosol excipients (mannitol, trehalose and leucine). Powder 
formulations with excellent aerodynamic properties (fine particle fraction of up to 68%) were 
obtained with particle size (D50) in the 2.5 µm range, low moisture content (<5%), and high 
glass transitions temperatures, i.e. formulation attributes all suitable for inhalation application. 
In aqueous medium, dry powders rapidly disintegrated into the original polymer-protein 
nanocomplexes which provided protection towards proteolytic degradation. Taken together, 
the present study shows that dry powders based on (mPEG2k-polyGA)-protein nanocomplexes 
possess potentials as an inhalation delivery system.  
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1. Introduction 
In recent years, pulmonary drug delivery has received increasing attention due to the 
physiological characteristics of the respiratory system which allows local, but also systemic, 
therapies (Scheuch et al., 2006). With large surface area and avoidance of first-pass 
metabolism, pulmonary delivery has become a very attractive strategy for the delivery of new 
therapeutic agents, especially for peptides and proteins (Hussain et al., 2004; Malik et al., 
2007). Despite these advantages, challenges associated with the formulation of inhaled native 
proteins and their direct delivery to the lung epithelium (Dailey et al., 2003) - including poor 
bioavailability, side effects, denaturation/instability and frequent inability to cross the epithelial  
physiological barrier -  still exist (Klingler et al., 2009; Niven, 1995; Nyambura et al., 2009; 
Umashankar et al., 2010). In vivo lung clearing mechanisms of biotherapeutics include 
mucociliary and macrophage clearance, and degradation by lung proteases (Depreter et al., 
2013). To address the latter, co-administration of exogenous protease inhibitors has been 
investigated, although cytotoxicity of some inhibitors (Park et al., 2007), and the possibility of 
unbalancing the protease/anti-protease equilibrium, with consequent alteration of airway 
surface liquid homeostasis (Garcia-Verdugo et al., 2010), can be a significant issue (Depreter 
et al., 2013). Thus, alternative routes able to complement current approaches are still much 
needed. 
Polymeric nanoparticles have been investigated as potential formulations for pulmonary 
delivery of protein therapeutics (Bailey and Berkland, 2009), as they can offer protection from 
degradation both during storage and in vivo, can enhance transepithelial transport (Fowler et 
al., 2013a; Fowler et al., 2013b), and can reduce immunogenicity (Soppimath et al., 2001; Sung 
et al., 2007). However, polymeric materials with slow degradation profiles can potentially lead 
to pulmonary accumulation of nanoparticles, especially when daily administration is needed 
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(Dunne et al., 2000), resulting in long-term toxicity in the lungs (Armstrong et al., 1996; 
Sivadas et al., 2008). Within this context, formulations based on drug complexes with 
polymeric materials that possess relatively shorter life-time in the lung, such as ‘soluble’ 
polymer-protein nanocomplexes, could overcome pulmonary accumulation issues while still 
providing protection and opportunities for cellular targeting and intra/transcellular transport. 
These can be prepared by mixing of protein and polymeric solutions to form complexes based 
on non-covalent molecular interactions that can be reversed under specific conditions (Nieto-
Orellana et al., 2017) to release the protein therapeutic in vivo.   
 
Protein nanocomplexes are commonly formulated in aqueous solutions. However, major 
protein degradation mechanisms including de-amidations and hydrolysis are ‘water-mediated’ 
(Depreter et al., 2013). Moreover, aqueous solutions and suspensions are susceptible to 
microbial growth, which can promote the contamination of pulmonary devices, especially those 
used for chronic treatments (Jarvis et al., 2014). Within this context, dry powders are an 
attractive alternative for the delivery of protein therapeutics to the lungs. Spray-drying is the 
most common technique utilised for the production of inhalable dry powder formulations of 
protein therapeutics (Maltesen et al., 2008; You et al., 2007). For efficient deposition in the 
lungs, particles must possess specific particle size, density, and shape - collectively defined as 
the aerodynamic diameter (Carvalho et al., 2011). However, spray-drying of aqueous solution 
of proteins can induce aggregation and/or loss of activity (Adler and Lee, 1999; Haque and 
Adhikari, 2015; Maury et al., 2005a; Tzannis and Prestrelski, 1999), which must be minimised 
through ad hoc formulation strategies. Most of the currently available commercial inhalation 
products use lactose as a carrier material (Pilcer et al., 2012). However, lactose may not be 
always suitable for formulations of actives that contain primary amino groups, such as peptides 
and proteins, because of a range of potential side-reaction occurring at the sugar reducing end 
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(e.g. Maillard reaction), especially when the formulation process requires higher temperatures 
(Littringer et al., 2012a). Therefore, non-reducing sugars such as mannitol and trehalose have 
been investigated as potential alternatives (Littringer et al., 2012b; Maury et al., 2005a).  
 
Recently, we reported that mPEG2k-poly(glutamic acid) copolymers with  linear A-B (mPEG2k-
lin-polyGA), and miktoarm A-B3 (mPEG2k-mik-(polyGA)3) architectures can be successfully 
utilized in reversible protein complexation (Nieto-Orellana et al., 2017). At physiological pH, 
the polyGA block(s) possess multiple copies of anionic carboxylate units which can complex 
positively charged amino acids at the surface of protein molecules (lysozyme was utilized as a 
model protein). In the present study, we aimed to fabricate these non-covalent polymer-protein 
nanocomplexes into inhalable spray-dried powders suitable for pulmonary delivery. The 
aerosolisation properties of dry powders formulated from polymer-protein nanocomplexes 
were investigated using trehalose, mannitol and/or leucine as typical aerosol excipients. 
Leucine as a dispersion enhancer plays a crucial role in promoting de-aggregation of 
microparticles by limiting interparticulate forces, while trehalose and mannitol are common 
protective agents for biopharmaceuticals during both formulation and storage (Bakaltcheva et 
al., 2007; Hulse et al., 2008; Jin et al., 2010; Kibbe and Association, 2000; Maa et al., 1997; 
Ogain et al., 2011; Schüle et al., 2007; Torrado and Torrado, 2002). The lung possesses a wide 
range of pulmonary peptidases that function as specific clearance mechanisms for proteins and 
peptides, resulting in possible degradation/inactivation of applied biotherapeutic protein. Here, 
we show that the protein-polymer nanocomplexes liberated from dry powder formulations in 
aqueous medium possess a crucial ability to preserve protein activity.  
 
2. Materials and methods.   
2.1 Materials.   
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Sodium phosphate dibasic (99.9%), sodium phosphate monobasic dehydrate (≥99.0%), 
phosphoric acid, Micrococcus lisodeikticus lyophilised cells, trypsin from bovine pancreas, 
poly(allyl amine) solution (Mw 17,000 g mol-1), L-leucine, D-mannitol and D-(+)-trehalose 
dihydrate were purchased from Sigma Aldrich. Lysozyme molecular biology grade and BCA 
protein assay kit was supplied by AppliChem and ThermoFisher Technologies, respectively.  
 
Linear mPEG2k-lin-GA10 and mPEG2k-lin-GA30; and miktoarm mPEG2k-mik-(GA10)3 and 
mPEG2k-mik-(GA30)3 copolymers were synthetized by ring-opening polymerization of γ-
benzyl-L-glutamate N-carboxyanhydride (NCA) monomer from appropriate ω-amino 
poly(ethylene glycol)s, as previously described (Nieto-Orellana et al., 2017).  
2.2 Preparation of polymer-protein nanocomplexes. 
(mPEG2k-polyGA)-lysozyme nanocomplexes were prepared at relative molar charge ratio r = 
2.5 where r is the charge ratio between the number of glutamic acid residues present in the 
copolymer (negatively charged at physiological pH) and that of protein lysine and arginine 
residues (17 in total per protein molecule positively charged at physiological pH) of lysozyme. 
Polymers and protein were separately dissolved in phosphate buffer (PB, 10 mM, pH 7.4) and 
appropriate aliquots were mixed to achieve r = 2.5 (Nieto-Orellana et al., 2017). 
2.3 Preparation of the liquid feed for spray-drying. 
To prepare ‘liquid feed’ for spray drying, 37.5 mL of nanocomplex suspension (2 mg mL-1) 
was added to 37.5 mL of the excipients solution in deionized water, as summarized in ESI, 
Table S1. The final total solid content of the suspension was always kept constant at 1 % (w/v). 
The suspension was gently stirred on a roller for 30 min at room temperature prior to spray-
drying. The components of the resulting dry powders were as follows: 0-10 % (w/w) 
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nanocomplexes or 5% (w/w) lysozyme, 0-10 % (w/w) leucine, 6.6 % (w/w) phosphate buffer 
salts, and trehalose or mannitol as bulking agents (up to 100 % (w/w)).  For example, for the 
Up to 100% Trehalose formulations (Table 1), the following compositions apply:  
- control formulation containing no lysozyme: 0% nanocomplexes (w/w), 6.6 % (w/w) 
phosphate buffer salts, 93.4 % (w/w) trehalose. 
- control formulation containing un-complexed free lysozyme (dry powder formulation that 
contains lysozyme only, with no copolymer added): 0% nanocomplexes (w/w), 5 % free 
lysozyme (w/w), 6.6 % (w/w) phosphate buffer salts, 88.4 % (w/w) trehalose 
- formulations containing [mPEG2k-(poly(glutamic acid))-lysozyme] nanocomplexes: 10% 
nanocomplexes (w/w), 6.6 % (w/w) phosphate buffer salts, 83.4 % (w/w) trehalose. 
 
 
2.4 Spray-drying conditions. 
Laboratory scale spray-drying equipment developed by Vectura Group plc (Chippenham, 
United Kingdom) was used to produce the dry powders. The optimal operating conditions 
were: total solids content: 1 % (w/v), atomization air flow rate: 15 L min-1, atomization air 
pressure: 2.5 bar, air outlet temperature: 65°C, liquid feed flow rate: 2.5 mL min-1, drying air 
flow rate 17 kg h-1 and drying gas pressure: 2.0 bar. The resulting dry powder formulations 
were handled and stored at low humidity (<30 %).  
The yield was calculated as the ratio between the weight of solids collected after spray-drying 
and that of the initial amount of ingredients used to prepare the aqueous solutions, expressed 
as a percentage (%).  
2.5 Dry powder characterization 
2.5.1 Particle size distribution and morphology 
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Particle size distribution of sprayed samples was measured by laser diffraction (ASPIROS 
Sympatec, Clausthal-Zellerfeld, Germany). Powders were dispersed through the measurement 
zone under a dispersion pressure of 2.0 bar using the R2 lens. The measurements were 
performed in triplicate. Size is reported as mean volumetric diameter (D50) and distribution 
width is presented as span. Span index is calculated as follows:  
Span=
D90-D10
D50
 
where D10, D50 and D90 are the diameters below which 10 %, 50 % and 90 % of the particle 
population lie, respectively. The morphology of the particles was visualized by scanning 
electron microscopy (SEM). The samples were mounted onto aluminum stubs and sputter 
coated (20 nm) with gold/palladium target using a Quorum Q15 TES coating unit. The samples 
were viewed using a Hitachi S3000H Scanning Electron Microscope with an accelerating 
voltage of 10 kV.  
2.5.2 Moisture content 
Particle moisture content was measured immediately after spray-drying by thermogravimetric 
analysis under non-oxidizing conditions (TGA 4000). For the analysis, 10-20 mg of powder 
were heated from 20 ºC to 160 ºC at 10 ºC min-1 and maintained at the final temperature for 5 
min before measurement.  
2.5.3 Protein incorporation efficiencies 
The amount of protein encapsulated in the dry powders was evaluated by bicinchoninic acid 
(BCA) assay. Dry powders were first incubated in PB for 1 h under gentle stirring, at room 
temperature – at a theoretical protein concentration of 15-25 µg mL-1 (mass of protein assuming 
100 % protein incorporation). Then 150 µL of particle samples and 150 µL of BCA solution 
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prepared as described by the manufacturer (BCA protein assay kit, ThermoFisher 
Technologies) were mixed and heated at 56ºC for 60 min. Once cooled down to 25ºC, the 
absorbance was measured at λ = 562 nm using a micro-plate reader (SpectraMax M2). All the 
absorbance values were corrected by subtracting the values measured for relevant blank 
samples. Each measurement was performed in quadruplicate. The protein encapsulation (%) 
was calculated as a percentage between the amount of protein in the dry powder, determined 
from a calibration curve, and the amount of protein present in the liquid feed.  
2.5.4 Differential scanning calorimetry (DSC) 
Samples were prepared in closed aluminum pans. 2-3 mg of powders was heated from 10°C to 
60°C at 10°C min-1 and then cooled down to 10°C. This process was then repeated 3 times, 
increasing the temperature to 130°C, 140°C and 230°C, respectively. Glass transition (Tg), heat 
capacity (∆Cp), melting point (Tm) and enthalpy of melting (∆Hm) were derived from the 
resulting thermograms. 
2.5.5 In vitro pulmonary deposition. 
The aerodynamic properties of dry powders were assessed using a fast screening impactor (FSI, 
Copley Scientific). A standard dispersion procedure was conducted for 4 s at an air flow rate 
of 60 L min-1. The cut-off aerodynamic diameter was 5 µm. An amount of 12 ± 1 mg of powder 
was loaded into blisters and aerosolised using a proprietary unit dose DPI (Vectura, UK). The 
emitted dose (ED) was calculated by accurately weighing the blister before and after 
aerosolization. Particles with an aerodynamic diameter lower than 5 µm were deposited on a 
filter in the fine fraction collector. The filter was weighed before and after dispersion, in order 
to determine the fine particle fraction (FPF), which can be defined as the fraction (%) of the 
emitted dose (ED) with an aerodynamic diameter below 5 µm. Each powder was tested in 
triplicate.  
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2.6 Nanocomplexes recovery from dry powders in aqueous medium 
To investigate whether the nanocomplexes could be recovered in their initial size from the dry 
powders, the latter samples were incubated in PB for 15 min under gentle stirring at room 
temperature at a protein concentration of 70 µg mL-1 (as quantified by BCA assay). The 
hydrodynamic diameter of particles in such formed suspension was then measured by 
nanoparticle tracking analysis (NTA) using a Nanosight LM14. All measurements were 
performed at 25°C. NTA 2.0 Build 127 software was used for data capturing and analysis. The 
samples were measured for 80 s. Particle size distributions are represented here as normalized 
distributions where the particle size of the largest population is taken as 100 %. 
2.7 Lysozyme activity  
The enzymatic activity of lysozyme, was measured by a turbidimetric enzymatic assay where 
the decrease in optical density of a suspension of Micrococcus lysodeikticus lyophilized cells, 
a natural substrate for lysozyme, in PB was monitored (Tomita et al., 2010). Nanocomplexes 
or free lysozyme were extracted from the dry powders as described above and the protein 
concentration was adjusted to 37 µg mL-1 (as quantified by BCA assay). 10 mg of lyophilized 
cells were added to 20 mL of PB. 300 µL of this substrate suspension were added to 150 µL of 
nanocomplexes suspension and the decrease in optical density (OD) was measured at λ = 460 
nm as a function of time, for 60 sec. The OD decay plots from 0 to 10 sec were fitted to a linear 
equation and the enzymatic activities were then determined from the slope of the fitted line.  
To recover lysozyme from the polymer nanocomplexes, in order to assess its residual 
enzymatic activity, 480 μg of poly(allyl amine) competitive ligand were added to 2 mL of the 
nanocomplex suspension (corresponding to a lysozyme concentration of 37 µg mL-1) to 
sequester lysozyme from mPEG-polyGA complexes, and the mixture was maintained under 
very gentle stirring for 1 h at room temperature. The lysozyme activity in the resulting solution 
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was then quantified as described above. Unprocessed, ‘free’ lysozyme was used as reference 
(100 % enzymatic activity). All enzymatic activity experiments were carried out in triplicate. 
2.8 (mPEG-polyGA)-lysozyme complexes: stability against proteolytic degradation. 
To assess the protein protection capability of the nanocomplexes against enzymatic 
degradation, these were first recovered from the dry powders as described above, the protein 
concentration adjusted to 37 µg mL-1 (as quantified by BCA assay) and 657 µg of trypsin added 
to 4 mL of nanocomplex suspension. The mixture was kept at room temperature for 3 h under 
gentle stirring. 480 µg of poly(allyl amine) was added to the mixture and gently stirred for 1 h. 
Lysozyme activity was quantified as described above. All enzymatic activity experiments were 
carried out in triplicate.  
2.9 Statistical analysis 
Measurements were carried out in triplicate, unless otherwise stated. Values are given as means 
± SD. The statistical significance of the results was assessed using one-way analysis of variance 
(ANOVA), Dunnet’s multiple comparisons test. 
 
3. Results and Discussion 
3.1.  Formulation and characterization of (mPEG2k-polyGA)-lysozyme dry powders 
In this work we used two A-B linear and two A-B3 miktoarm copolymers of mPEG2kDa-polyGA 
recently developed, consisting of one 2.0 kDa monomethoxy polyethylene glycol, (mPEG2k), 
arm (A) and one, or three, respectively, poly(glutamic acid), poly(GA), branches (B) of 
variable chain length, which allow for complexation with positively charged amino acids 
within protein molecule (Figure 1). 
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Figure 1. Chemical structure of miktoarm (left) and linear (right) mPEG2k-polyGA copolymers used in this work. 
We previously demonstrated that biocompatible linear and miktoarm mPEG2k-polyGA 
copolymers were capable of non-covalent protein complexation in aqueous solution under 
appropriate conditions. We also showed that protein molecules were predominantly located in 
the “core” of these nano-assemblies and that protein integrity was not negatively affected by 
polymer complexation (Nieto-Orellana et al., 2017). Here, we further explored the therapeutic 
potential of this technology by investigating if (mPEG2k-polyGA)-protein nanocomplexes can 
be efficiently formulated into inhalable spray-dried powders. The resulting formulations were 
characterised in terms of particle size, moisture content, thermal properties, encapsulation 
efficiency, aerodynamic properties, and protein protection to assess their suitability for 
inhalable dry powder formulations. Due to its 6 lysine and 11 arginine residues positively 
charged at physiological pH (Masuda et al., 2005) and an isoelectric point at pH 11.3 (Wetter 
and Deutsch, 1951), lysozyme was chosen as a representative positively charged protein which 
can be reversibly complexed with polyanionic polymer moiety. In a previous study, we have 
optimized the complexation conditions of lysozyme with mPEG2k-polyGA (Nieto-Orellana et 
al., 2017). That work was further expanded here to assess developability of the complexes for 
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formulation into inhalation dry powders by spray-drying. Additionally, the biological i.e. 
enzymatic activity of lysozyme can be routinely assessed through an established assay, making 
this protein substrate particularly suitable for monitoring potential loss of functional activity 
following processing by spray-drying.    
While investigation of metabolism (biodegradability) of the mPEG2k-polyGA materials in the 
lung is beyond the scope of the present study, these polymers were designed to be degradable 
in vivo. Poly(glutamic acid) can be hydrolysed into its aminoacid constituents by a range of 
proteases, particularly cysteine proteases, including cathepsin B and cathepsin L (Melancon et 
al., 2007).  Cathepsin B is secreted by a number of pulmonary cells, and has been found in both 
healthy and diseased lung tissues (Werle et al., 1994; Heidtmann et al., 1997; Křepela et al., 
1995). Conversely, cathepsin L is stably expressed in bronchiolar epithelial cells (Okudela et 
al., 2016). One can expect that, once the poly(glutamic acid) is enzymatically hydrolysed, the 
short residual PEG of 2000 Da molecular weight would be cleared from the lungs. Indeed, 
Gursahani et al have shown that short PEGs (< 2000 Da) were efficiently cleared from rat lungs 
within 48 h  (Gursahani et al., 2009). 
Polymer-protein nanocomplexes were first assembled by mixing mPEG2k-polyGA copolymers 
and lysozyme at relative molar charge ratio of 2.5:1 (defined as the ratio between the number 
of glutamic acid residues present in the copolymer and negatively charged at physiological pH, 
and the protein lysine and arginine residues, respectively) in 10 mM phosphate buffer, pH 7.4. 
The toxicological profile of free mPEG2k-polyGA copolymers and their complexes with 
lysozyme, was assessed in the human alveolar (A549) and human bronchial (Calu-3) epithelial 
cell lines by both metabolic activity (MTS) and lactate dehydrogenase (LDH) assays after a 4 
or 24 hour treatment. Both the copolymers alone, and the corresponding lysozyme 
nanocomplexes were found non-cytotoxic within the range of polymer concentrations 
investigated (0-200 µg mL-1, Figure S3 & S4, Supporting Information). The resulting 
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nanocomplexes were then formulated into dry powders by spray drying - using typical aerosol 
excipients trehalose or mannitol and leucine - to form potentially inhalable dry powder of 
micron-size range particles. Trehalose was used as a bulk agent as it is a well-established 
stabiliser for bio-molecules formulations that are sensitive to loss of activity and structural 
integrity during desiccation. The rigid amorphous matrix created by trehalose below its glass 
transition temperature is believed to stabilise biological molecules by reducing rate of 
degradation reactions (Hulse et al., 2008; Jin et al., 2010; Maa et al., 1997; Ogain et al., 2011). 
Furthermore, amorphous trehalose has been suggested to act as a substitute for water in the 
formation of hydrogen bonds with protein molecules, thus stabilising their three-dimensional 
structure in the dry state (Chang and Pikal, 2009; Vehring, 2008; Weers et al., 2007). In 
contrast, and due to its relatively low Tg (11°C), mannitol tends to recrystallise during spray-
drying (Weers et al., 2007). It therefore has a much lower protein stabilising ability, although 
its inherent physical stability is greater (Bakaltcheva et al., 2007; Kibbe and Association, 2000; 
Schüle et al., 2007; Torrado and Torrado, 2002). Leucine, a hydrophobic amino acid, is a well-
established dispersion enhancer which would normally be located on the surface of micron-
sized particles (typically < 10 µm) after spray-drying (Li et al., 2003; Vehring, 2008). In this 
way, it limits the interaction forces between particles and facilitates their dispersion and 
aerosolisation (Li et al., 2003; Vehring, 2008). Four formulations: trehalose, trehalose + 10% 
(w/w) leucine, mannitol, and mannitol + 10% (w/w) leucine, each containing either none or 
10% (w/w) of nanocomplexes or 5% (w/w) uncomplexed lysozyme - were tested in this study 
(Table1). 
The presence of (mPEG2k-polyGA)-lysozyme nanocomplexes, did not negatively affect the 
spray-drying yields of formulations containing trehalose+leucine, compared to control dry 
powders prepared with (5% w/w) of ‘free’ uncomplexed lysozyme model protein (Table 1). 
The nanocomplexes content in the dry powder formulations was kept constant at 10% w/w, 
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however, as the mPEG2k-polyGA polymers utilised to complex lysozyme had different 
molecular weights, the amount in weight of lysozyme varied, from 4.9-6.6 %, for each 
formulation prepared (ESI, Table S1). Thus, for the control dry powders containing 
uncomplexed free lysozyme, a 5% w/w lysozyme content, as a representative content in the 
nanocomplexes formulations, was chosen. Furthermore, the use of nanocomplexes 
significantly increased the yield of mannitol+leucine formulations from 30.9% using ‘free’ 
lysozyme, to 60.9% for the nanocomplexes samples (Table 1). Values between 40 and 60% 
yield are usually considered as satisfactory for lab-scale spray-dryers (Islam and Langrish, 
2010). For samples formulated without leucine, lower and more variable spray-drying yields 
were observed using both ‘free’ lysozyme and polymer-lysozyme nanocomplexes. It should be 
noted that formulations prepared with mannitol in absence of leucine were obtained with a very 
low yield and were not characterised further. No significant effect of (mPEG2k-polyGA) 
polymer size and topology on final yield was observed.  
 
Similarly, the presence of polymer-protein nanocomplexes in spray-dried powders had no 
detrimental effect on their particle size distribution (Table 1). For leucine-containing spray 
dried powders, median volumetric diameters (D50) were found to be in the 2-3 µm range, which 
is generally considered optimal for inhalation purposes (Labiris and Dolovich, 2003). The 
particle size distribution width (span values) of those powders was lower than 2, a value 
typically attributed to narrow particle size distributions (Palazzo et al., 2013).  Overall, the use 
of leucine helped in achieving satisfactory yields and particle size distributions suitable for 
inhalation dry powders. 
 
As described previously for these materials (Pourshahab et al., 2011), SEM analysis revealed 
that trehalose+leucine containing dry powders generally possessed a spherical shape and 
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relatively smooth surface (Figure 2, panels B and E), whilst particles from  mannitol+leucine 
had a rougher surface (Figure 2, images A and D), likely as a consequence of the crystalline 
nature of mannitol. The presence of leucine was found to be key to obtaining a well formed 
spherical morphology of the spray-dried powders (Figures 2 and S2). It is important to note 
that the presence of polymer-protein nanocomplexes had no noticeable negative impact on the 
morphology of the spray-dried powders (Figure 2, images A vs. D, and B vs. E).   
 
Table 1. Effect of formulation compositions on spray-drying yield, and particle size and span values.  
Excipients 
(w/w) 
Nanocomplexes 
(w/w) 
Yield (%)a D50 (µm)b Spanc 
Up to 100% Trehalose      no lysozyme (control)     41.2d 1.70 ± 0.01 1.95 ± 0.02 
 5% Free lysozyme 36.0 1.99e 1.78e 
 10% (mPEG2k-lin-GA10)-Lysozyme 15.3 2.48d 28.16d 
 10% (mPEG2k-lin-GA30)-Lysozyme 18.3 1.49e 1.17e 
 10% (mPEG2k-mik-(GA10)3)-Lysozyme 20.9 1.45e 1.81e 
 10% (mPEG2k-mik-(GA30)3)-Lysozyme 21.5 1.30e 1.46e 
Up to 100% Trehalose  
+ 10% Leucine 
no lysozyme (control)  76.4d 2.50 ± 0.02 1.77 ± 0.01 
 5% Free lysozyme 57.8 2.37 ± 0.03 1.74 ± 0.02 
 10% (mPEG2k-lin-GA10)-Lysozyme 55.6 2.43 ± 0.06 1.59 ± 0.02 
 10% (mPEG2k-lin-GA30)-Lysozyme 49.7 2.45 ± 0.02 1.61 ± 0.01 
 10% (mPEG2k-mik-(GA10)3)-Lysozyme 53.8 2.32 ± 0.07 1.67 ± 0.04 
 10% (mPEG2k-mik-(GA30)3)-Lysozyme 62.4 2.30 ± 0.02 1.73 ± 0.02 
Up to 100% Mannitol no lysozyme (control) 69.8d 2.29 ± 0.03 1.88 ± 0.01 
 5% Free lysozyme 11.5 5.79e 1.82e 
 10% (mPEG2k-lin-GA10)-Lysozyme 4.0 - - 
 10% (mPEG2k-lin-GA30)-Lysozyme 20.7 6.61d 1.70d 
 10% (mPEG2k-mik-(GA10)3)-Lysozyme 5.7 - - 
 10% (mPEG2k-mik-(GA30)3)-Lysozyme 8.6 - - 
Up to 100% Mannitol 
+ 10% Leucine 
no lysozyme (control) 78.0d 2.45 ± 0.06 1.80 ± 0.05 
 5% Free lysozyme 30.9 2.73 ± 0.04 1.75 ± 0.01 
 10% (mPEG2k-lin-GA10)-Lysozyme 54.3 2.62 ± 0.04 1.94 ± 0.02 
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All formulations also contained 6.6% (w/w) phosphate buffer salts. Experiments were carried out in triplicate unless specified 
otherwise. 
a Yield is calculated from the amount of solid mass obtained from the spray-drying divided by the total amount of 
solid ingredients delivered to the chamber of the spray-drier, expressed as a percentage. b Particle size, D50, denotes 
the size below which 50% of the particle population lie.  c Span=(D90-D10)/D50, where D10, D50 and D90 are the 
diameters below which 10 %, 50 % and 90 % of the particle population lie, respectively. d Protein-free dry powder 
formulations were prepared on a larger (two-fold) scale which for laboratory scale spray-drying can lead to higher 
yields. e Data obtained from single or duplicate measurements. ‘ – ‘indicates that no measurement was performed due 
to the low amount of material obtained after spray-drying. 
 
 
Figure 2.  Representative scanning electron microscopy (SEM) images of dry powders. Samples contain ‘un-
complexed lysozyme’ (A, B and C), and lysozyme-(mPEG2k-mik-(GA30)3) nanocomplexes (D, E and F). ‘Un-
complexed lysozyme’ refers to dry powder formulations that contain lysozyme only, with no copolymer added. 
Excipients: mannitol + leucine (A, D), trehalose + leucine (B, E), or mannitol (C, F). All formulations also contain 
6.6% (w/w) phosphate buffer salts. 
 
Polymer-protein nanocomplexes were found to be efficiently incorporated into dry powders 
with encapsulation efficiencies between 80 and 100% (Figure 3). The excipients or the 
complexing polymers had no pronounced impact on the encapsulation efficiency.  
Mannitol + Leucine Trehalose + Leucine Mannitol
Un-complexed lysozyme
(mPEG2k-mik-(GA30)3)-lysozyme 
nanocomplexes
A B C
10 μm5 μm5 μm
D FE
5 μm5 μm 5 μm
 10% (mPEG2k-lin-GA30)-Lysozyme 60.9 2.66 ± 0.14 1.74 ± 0.03 
 10% (mPEG2k-mik-(GA10)3)-Lysozyme 52.0 2.50 ± 0.01 1.70 ± 0.01 
 10% (mPEG2k-mik-(GA30)3)-Lysozyme 48.6 2.58 ± 0.06 1.63 ± 0.02 
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Figure 3.  Protein encapsulation efficiency for dry powder formulations prepared using trehalose (up to 100% 
(w/w)), trehalose (up to 100% (w/w)) + leucine (10% (w/w)), mannitol (up to 100% (w/w)), and mannitol (up to 
100% (w/w)) + leucine (10% (w/w)) as excipients. All formulations also contain 6.6% (w/w) phosphate buffer 
salts. All experiments were carried out in quadruplicate. 
 
Differential scanning calorimetry (DSC) analysis was performed to further evaluate the 
physical properties of the dry powders formulated (Table 2). Amorphous trehalose containing 
dry powders showed a glass transition temperature (Tg) between 124 and 131 °C, indicating 
these formulations are likely to be stable in normal storage conditions. The values obtained are 
higher than those reported for dry pure trehalose - e.g. 106 °C (Roe and Labuza, 2005), and 
121 °C (Grasmeijer et al., 2013) - likely due to the presence of phosphate buffer salts and/or 
protein-polypeptide complexes in the tested formulations (Ohtake et al., 2004) (Bellavia et al., 
2009).  In terms of overall stability of tested dry powders, the Tg of control trehalose 
formulation is already well above standard storage temperatures, thus the increase in glass 
transition temperature observed in the presence of buffer salts and/or protein-polypeptide 
complexes is not likely to result in further significant stabilisation of the formulations.  
 
For crystalline mannitol based dry powders, an endothermic melting transition (Tm) between 
148 and 162°C typical of crystalline mannitol was observed (Ong et al., 2014; Takada et al., 
2009).  
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Moisture content was found to be lower than 5% for all spray dried powders, achieving values 
in the range of 0.5 – 2.0 % for mannitol containing dry powders, likely due to their crystalline 
nature (ESI, Table S2). Such water content is typical of spray-dried protein formulations 
(Bosquillon et al., 2004) (Balducci et al., 2014; Maury et al., 2005b) and indicates efficient 
drying of these materials under the selected operating conditions. Low moisture content in dry 
powders for pulmonary application is a desirable formulation attribute, as residual moisture 
can lead to an increase in powder cohesiveness or a reduction in the formulation glass transition 
temperature (Chang and Pikal, 2009).  
 
Table 2. Thermal behavior of dry powders tested in this study.  
      Excipients 
          (w/w) 
          Nanocomplexes 
               ( % w/w) 
            Tg (˚C) Tm (˚C) 
Up to 100% Trehalose                     no lysozyme (control) 130.6 -a 
 5% Free lysozyme 127.4 - a 
 10% (mPEG2k-lin-GA10)- lysozyme 128.0 -
 a 
 10% (mPEG2k-lin-GA30)- lysozyme 125.9 -
 a 
 10% (mPEG2k-mik-(GA10)3)- lysozyme 127.0 -
 a 
 10% (mPEG2k-mik-(GA30)3)- lysozyme 130.7 -
 a 
Up to 100% Trehalose  
+ 10% Leucine 
                    no lysozyme (control) 128.7 - a 
 5% Free lysozyme 126.4 - a 
 10% (mPEG2k-lin-GA10)- lysozyme 124.2 -
  a 
 10% (mPEG2k-lin-GA30)- lysozyme 126.7 -
 a 
 10% (mPEG2k-mik-(GA10)3)- lysozyme 129.2 -
  a 
 10% (mPEG2k-mik-(GA30)3)- lysozyme 129.5 -
 a 
Up to 100% Mannitol                     no lysozyme (control) - b 162.4 
 5% Free lysozyme - b 159.4 
 10% (mPEG2k-lin-GA10)- lysozyme -
 b 158.0 
 10% (mPEG2k-lin-GA30)- lysozyme -
 b 148.6 
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All formulations also contained 6.6% (w/w) phosphate buffer salts. Tg and Tm are represented as the average value 
of two individual measurements. 
a ‘-‘ indicates that no Tm was observed; trehalose is amorphous compound;  b ‘-‘ denotes that no Tg was observed due 
to crystalline nature of mannitol. 
 
 
3.2.  Aerosolisation performance 
In the development of dry powders for pulmonary drug delivery, the Emitted Dose (the 
percentage of the mass of a formulation exiting a given device after inhalation, ED) and Fine 
Particle Fraction (the fraction of particles with an aerodynamic diameter below 5 µm, hence 
suitable for pulmonary delivery, FPF) are essential formulations attributes. The ED values 
obtained with the majority of the formulations developed in this study were in the >80 - 100% 
range. The exceptions were some trehalose containing powders: pure trehalose, the formulation 
containing uncomplexed protein, and the formulation of (mPEG2k-polyGA)30-protein 
nanocomplexes. These data are not unexpected, as powders with a high content of trehalose 
have been shown to possess poor aerosolisation properties, attributed to the highly hygroscopic 
and adhesive nature of amorphous trehalose (Maa et al., 1997).  
 
The trehalose, mannitol and mannitol+leucine containing formulations exhibited a FPF < 40%, 
while values > 60% were obtained for the trehalose+leucine dry powders (Figure 4); this could 
indicate a potential for a high dry powder deposition in the lungs. A large content of mannitol 
 10% (mPEG2k-mik-(GA10)3)- lysozyme -
 b 159.4 
 10% (mPEG2k-mik-(GA30)3)- lysozyme -
 b 159.5 
Up to 100% Mannitol  
+ 10% Leucine 
                    no lysozyme (control) - b 160.8 
 5% Free lysozyme - b 158.0 
 10% (mPEG2k-lin-GA10)- lysozyme -
 b 158.7 
 10% (mPEG2k-lin-GA30)- lysozyme -
 b 147.9 
 10% (mPEG2k-mik-(GA10)3)- lysozyme -
 b 158.0 
 10% (mPEG2k-mik-(GA30)3)- lysozyme -
 b 158.2 
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has been previously shown to adversely affect the respirable fraction of spray-dried powders, 
likely a consequence of the formation of particle aggregates (Bosquillon et al., 2001). Leucine 
improved the aerosolisation performances of powders prepared with both sugars (Figure 4, p < 
0.05).  This is in line with the general consensus in the literature, where a small proportion of 
a surface active molecule (e.g. leucine) is believed to be important to improve the dispersability 
of dry powder particles (Lechuga-Ballesteros et al., 2008; Li et al., 2003; Li et al., 2005; Lucas 
et al., 1999). It should also be noted that low yields (< 40%) were obtained following spray-
drying of both trehalose and mannitol leucine-free formulations, potentially due to material 
aggregation and low dispersability.  Importantly, the presence of protein nanocomplexes within 
the formulations did not have a detrimental effect on the aerodynamic properties (ED and FPF) 
of the most performant dry powders made of trehalose+leucine. 
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Figure 4. Fine particle fraction (FPF) and emitted dose (ED) of trehalose (up to 100% (w/w)); trehalose (up to 
100% (w/w)) + leucine (10% (w/w)); mannitol (up to 100% (w/w)); and mannitol (up to 100% (w/w)) + leucine 
(10% (w/w)) dry powders. ‘Control’ denotes blank powder formulation that contains only excipient(s) without 
lysozyme or copolymer, and ‘uncomplexed lysozyme’ denotes dry powder formulation that contains no 
copolymer. All formulations also contained 6.6% (w/w) phosphate buffer salts. All experiments were carried out 
in triplicate. FPF and ED values from mannitol dry powders were obtained from single, double or triple 
measurements due to low material quantity obtained. One-way ANOVA was used for statistical analysis. * p < 
0.1, ** p < 0.01 *** p < 0.001, **** p < 0.0001.  
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3.3.  Recovery, protein activity and protein protection against proteolytic degradation  
The formulated dry powders ability to ‘release’ the original polymer-protein nanocomplexes 
when suspended in an aqueous environment was evaluated by their exposure to pH 7.4 
phosphate buffer; the pH of the airway lining fluid has been reported to be around 7.0 
(Jayaraman et al., 2001). Following a 15-minutes incubation, a particle size analysis was 
conducted on the resulting suspension by nanoparticle tracking analysis (NTA), a method used 
previously (Dragovic et al., 2011; Nieto-Orellana et al., 2017). The particle size distribution of 
samples recovered following dispersion of dry powders in the buffer appears to be no 
significantly different to that for (mPEG2k-polyGA)-lysozyme nanocomplexes before spray-
drying (Figure 5). Overall, these data showed that under the conditions chosen for the 
preparation of these spray-dried formulations, the integrity of the nanocomplexes was not 
compromised, and that they could be recovered upon dispersion of dry powders in aqueous 
medium.  
No particle size profile could be generated by NTA upon dispersion in the buffer of 
formulations containing un-complexed lysozyme, or free mPEG2k-polyGA polymer, 
confirming that the nano-sized assemblies measured in the nanocomplexes containing 
formulations were indeed polymer-protein complexes. 
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Figure 5. Particle size (hydrodynamic diameter) as measured by nanoparticle tracking analysis (NTA) of protein-
(mPEG2k-polyGA)-lysozyme nanocomplexes before spray-drying (A) and spray-dried powder formulations 
following incubation in phosphate buffer (PB, 10 mM, pH 7.4) at 70 µg mL-1 protein concentration; 
mannitol+leucine (B), mannitol (C), trehalose+leucine (D), and trehalose (E) containing dry powders.  
 
To evaluate the stability of the protein following spray-drying, enzymatic activity of 
incorporated lysozyme was evaluated by a turbidimetric assay using Micrococcus lysodeikticus 
as the substrate. All nanocomplexes recovered from the dry powders following suspension in 
phosphate buffer exhibited a lower enzymatic activity than un-complexed lysozyme recovered 
from the corresponding formulation (Figure 6). This was not unexpected, as we previously 
observed that complexation of lysozyme with mPEG2k-polyGA polymers into non-covalent 
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complexes profoundly reduced its enzymatic activity (Nieto-Orellana et al., 2017). Although 
this is not fully elucidated, it is probable that the enzyme active site becomes less accessible to 
the substrate upon the protein’s complexation with the polymers. However, 70-100% of the 
lysozyme activity from nanocomplexes could be recovered upon addition of excess of 
poly(allyl amine); a polycationic polymer which sequesters polyanionic polymers (Tomita et 
al., 2010) such as poly(glutamic acid) block of (mPEG2k-polyGA) copolymers, inducing 
complex disassembly and release of the ‘free’ lysozyme (Figure 6). Poly(allyl amine) was 
employed here as a tool to recover lysozyme from ionic polymer-protein complexes and assess 
its residual enzymatic activity, in analogy to previous studies by Shiraki and co-workers 
(Kurinomaru et al., 2014; Kurinomaru et al., 2012; Tomita et al., 2010). Whilst further studies 
on in vivo release kinetics are needed, these results suggest that the release of protein from 
nanocomplexes could occur in a ‘competitive dissociation conditions’ – e.g. the presence of 
charged species or local differences in pH and ionic strength.  
Interestingly, it appears that complexation with mPEG2k-polyGA copolymers, especially 
mPEG2k-lin-GA30 in mannitol+leucine dry powder formulations, could provide protection 
against lysozyme partial loss of activity following production of the dry powders formulations 
(Figure 6). However at this stage, due to the observed high preservation of ‘free’ lysozyme’s 
enzymatic activity on processing under described spray-drying conditions, we cannot 
confidently confirm whether the complexation with the mPEG2k-polyGA copolymers indeed 
protects stability and biological activity of the complexed protein. The protective potential of 
the copolymers investigated in this study should be tested using biologicals shown to be prone 
to degradation upon spray-drying and/or mannitol crystallization, such as β-galactosidase or 
alcohol dehydrogenase (Estevinho et al., 2015; Shiga et al., 2014), and will be the subject of 
future communications.  
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Figure 6. Lysozyme enzymatic activity. Trehalose, trehalose+leucine, mannitol and mannitol+leucine dry 
powders investigated in this study. ‘Un-complexed lysozyme’ is a dry powder formulation that contains lysozyme 
only, with no copolymer added. All experiments were carried out in triplicate. Un-complexed free lysozyme was 
used as a reference (100% enzymatic activity). One-way ANOVA was used for statistical analysis. * p < 0.1, ** 
p < 0.01 *** p < 0.001, **** p < 0.0001. 
 
Finally, the ability of (mPEG2k-polyGA)-lysozyme complexes to protect the enzyme from 
proteolytic degradation was assessed. A selection of peptidases has been found in the lung of 
humans and other mammalians, including cathepsin B, collagenase, elastase chymotrypsin, 
aminopeptidase P, neutrophil proteases and a range of carboxypeptidases (Fujita et al., 1990; 
Janoff et al., 1983; Orlowski et al., 1981; Stratford and Lee, 1986; Wall and Lanutti, 1993). In 
this study trypsin, which exclusively cleaves arginine and lysine residues at the protein C-
terminal end (Olsen et al., 2004), was employed as a model proteolytic enzyme capable of 
degrading lysozyme, but not the mPEG2k-polyGA copolymers (which do not possess Arg or 
Lys residues), which simplified the interpretation of experimental results.  
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The nanocomplexes were exposed to trypsin for 3 hours, under conditions previously shown 
to be sufficient for the enzyme to degrade lysozyme and then be auto-digested (Fraser and 
Powell, 1950). Following the incubation with enzyme, poly(allyl amine) was added with the 
aim to release lysozyme from the (mPEG2k-polyGA) nanocomplexes. When not complexed 
with the copolymers, lysozyme activity was in the present study reduced to less than 40% of 
its initial value (Figure 7). Non-covalent complexation with mPEG2k-polyGA copolymers 
tested was able to provide protection to complexed lysozyme against enzymatic degradation, 
whereby mPEG2k-lin-GA30 appears to be the most efficient. This is in agreement with our 
previous studies that demonstrated superior ability this copolymer to complex lysozyme, 
compared to the other members of this polymer library (Nieto-Orellana et al., 2017).  
Figure 7. (mPEG2k-polyGA)-lysozyme complexes: protection against lysozyme proteolytic degradation. 
Lysozyme activity was measured after incubation of the dry powders in the presence of trypsin for 3 h, followed 
by treatment with poly(allyl amine) for 1 h. Trehalose, trehalose+leucine, mannitol and mannitol+leucine dry 
powders were investigated in this study. All experiments were carried out in triplicate. Un-complexed free 
lysozyme was used as a reference (100% enzymatic activity). One-way ANOVA was used for statistical analysis. 
* p < 0.1, ** p < 0.01 *** p < 0.001, **** p < 0.0001. 
 
 
4. Conclusions 
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In the present study we demonstrated that a non-covalent protein complexes with mPEG2k-
polyGA copolymers, with either linear or miktoarm architecture, can be successfully 
formulated into spray-dried powders with product attributes appropriate for inhalation delivery. 
Typical inhalable aerosol excipients such as trehalose, mannitol and leucine were employed in 
the production, whereby the presence of leucine was found to be critical in obtaining a dry 
powder with spherical shape and particle size (D50 ˜ 2.5 µm) optimal for inhalation. The 
moisture content was found to be between 0.5- 5.0 %, a range appropriate for the stability of 
protein formulations. The best aerodynamic properties were observed for dry powders 
composed of trehalose+leucine+polymer-protein nanocomplexes, with FPFs as high as 68%, 
without any significant negative effect of nanocomplexes on powder properties. ‘Original’ 
protein-polymer nanocomplexes could be recovered from dry powder formulations, with 
protein retaining its enzymatic activity, especially when mPEG2k-lin-GA30 copolymer was 
employed in the complexation. The same copolymer also provided the best protection to the 
complexed protein against enzymatic degradation. Hence, dry powder formulations 
incorporating non-covalent polymer-protein nanocomplexes have attributes appropriate for 
efficient and protective inhalation delivery of proteins.  
 
ACKNOWLEDGMENT 
Vectura Group plc and the School of Pharmacy at the University of Nottingham are 
acknowledged for funding A. Nieto-Orellana’s PhD studentship.  
Nanoscale & Microscale Research Centre (NMRC) is acknowledged for providing the facilities 
for NTA analysis. 
 
5. REFERENCES 
Adler, M., Lee, G., 1999. Stability and surface activity of lactate dehydrogenase in spray‐
dried trehalose. J. Pharm. Sci. 88, 199-208. 
 28 
Armstrong, D.J., Elliott, P.N., Ford, J.L., Gadsdon, D., McCarthy, G.P., Rostron, C., 
Worsley, M.D., 1996. Poly-(D,L-lactic acid) microspheres incorporating histological dyes for 
intra-pulmonary histopathological investigations. J. Pharm. Pharmacol. 48, 258-262. 
Bailey, M.M., Berkland, C.J., 2009. Nanoparticle formulations in pulmonary drug delivery. 
Med. Res. Rev. 29, 196-212. 
Bakaltcheva, I., O'Sullivan, A.M., Hmel, P., Ogbu, H., 2007. Freeze-dried whole plasma: 
Evaluating sucrose, trehalose, sorbitol, mannitol and glycine as stabilizers. Thromb. Res. 120, 
105-116. 
Balducci, A.G., Cagnani, S., Sonvico, F., Rossi, A., Barata, P., Colombo, G., Colombo, P., 
Buttini, F., 2014. Pure insulin highly respirable powders for inhalation. Eur. J. Pharm. Sci. 
51, 110-117. 
Bellavia, G., Cottone, G., Giuffrida, S., Cupane, A., Cordone, L., 2009. Thermal 
Denaturation of Myoglobin in Water−Disaccharide Matrixes: Relation with the Glass 
Transition of the System. The Journal of Physical Chemistry B 113, 11543-11549. 
Bosquillon, C., Lombry, C., Préat, V., Vanbever, R., 2001. Influence of formulation 
excipients and physical characteristics of inhalation dry powders on their aerosolization 
performance. J. Controlled Release 70, 329-339. 
Bosquillon, C., Préat, V., Vanbever, R., 2004. Pulmonary delivery of growth hormone using 
dry powders and visualization of its local fate in rats. J. Controlled Release 96, 233-244. 
Carvalho, T.C., Peters, J.I., Williams, R.O., 3rd, 2011. Influence of particle size on regional 
lung deposition--what evidence is there? Int. J. Pharm. 406, 1-10. 
Chang, L.L., Pikal, M.J., 2009. Mechanisms of protein stabilization in the solid state. J. 
Pharm. Sci. 98, 2886-2908. 
Dailey, L.A., Schmehl, T., Gessler, T., Wittmar, M., Grimminger, F., Seeger, W., Kissel, T., 
2003. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and 
nanoparticle characteristics on aerosol features. J. Control. Release 86, 131-144. 
Depreter, F., Pilcer, G., Amighi, K., 2013. Inhaled proteins: challenges and perspectives. Int. 
J. Pharm. 447, 251-280. 
Dragovic, R.A., Gardiner, C., Brooks, A.S., Tannetta, D.S., Ferguson, D.J., Hole, P., Carr, B., 
Redman, C.W., Harris, A.L., Dobson, P.J., Harrison, P., Sargent, I.L., 2011. Sizing and 
phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. Nanomedicine 7, 780-
788. 
Dunne, M., Corrigan, O.I., Ramtoola, Z., 2000. Influence of particle size and dissolution 
conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials 
21, 1659-1668. 
Estevinho, B.N., Ramos, I., Rocha, F., 2015. Effect of the pH in the formation of β-
galactosidase microparticles produced by a spray-drying process. Int. J. Biol. Macromol. 78, 
238-242. 
Fowler, R., Vllasaliu, D., Falcone, F.H., Garnett, M., Smith, B., Horsley, H., Alexander, C., 
Stolnik, S., 2013a. Uptake and transport of B(12)-conjugated nanoparticles in airway 
epithelium. J. Controlled Release 172, 374-381. 
Fowler, R., Vllasaliu, D., Trillo, F.F., Garnett, M., Alexander, C., Horsley, H., Smith, B., 
Whitcombe, I., Eaton, M., Stolnik, S., 2013b. Nanoparticle transport in epithelial cells: 
pathway switching through bioconjugation. Small 9, 3282-3294. 
 29 
Fraser, D., Powell, R.E., 1950. The kinetics of trypsin digestion. J. Biol. Chem. 187, 803-820. 
Fujita, J., Nelson, N.L., Daughton, D.M., Dobry, C.A., Spurzem, J.R., Irino, S., Rennard, S.I., 
1990. Evaluation of elastase and antielastase balance in patients with chronic bronchitis and 
pulmonary emphysema. Am. Rev. Respir. Dis. 142, 57-62. 
Garcia-Verdugo, I., Descamps, D., Chignard, M., Touqui, L., Sallenave, J.-M., 2010. Lung 
protease/anti-protease network and modulation of mucus production and surfactant activity. 
Biochimie 92, 1608-1617. 
Grasmeijer, N., Stankovic, M., de Waard, H., Frijlink, H.W., Hinrichs, W.L.J., 2013. 
Unraveling protein stabilization mechanisms: Vitrification and water replacement in a glass 
transition temperature controlled system. Biochim. Biophys. Acta 1834, 763-769. 
Gursahani, H., Riggs-Sauthier, J., Pfeiffer, J., Lechuga-Ballesteros, D., Fishburn, C.S., 2009. 
Absorption of Polyethylene Glycol (PEG) Polymers: The Effect of PEG Size on 
Permeability. J. Pharm. Sci. 98, 2847-2856. 
Haque, M.A., Adhikari, B., 2015. Proteins in Spray Drying Process, in: Mujumdar, A.S. 
(Ed.), Handbook of Industrial Drying - Fourth Edition. CRC Press, pp. 971-983. 
Heidtmann, H.-H., Salge, U., Abrahamson, M., Bencina, M., Kastelic, L., Kopitar-Jerala, N., 
Turk, V., Lah, T.T., 1997. Cathepsin B and cysteine proteinase inhibitors in human lung 
cancer cell lines. Clin. Exp. Metastasis 15, 368-381. 
Hulse, W.L., Forbes, R.T., Bonner, M.C., Getrost, M., 2008. Do co-spray dried excipients 
offer better lysozyme stabilisation than single excipients? Eur. J. Pharm. Sci. 33, 294-305. 
Hussain, A., Arnold, J.J., Khan, M.A., Ahsan, F., 2004. Absorption enhancers in pulmonary 
protein delivery. J. Control. Release 94, 15-24. 
Islam, M.I.U., Langrish, T.A.G., 2010. An investigation into lactose crystallization under 
high temperature conditions during spray drying. Food Res. Int. 43, 46-56. 
Janoff, A., Raju, L., Dearing, R., 1983. Levels of elastase activity in bronchoalveolar lavage 
fluids of healthy smokers and nonsmokers. Am. Rev. Respir. Dis. 127, 540-544. 
Jarvis, S., Ind, P.W., Thomas, C., Goonesekera, S., Haffenden, R., Abdolrasouli, A., 
Fiorentino, F., Shiner, R.J., 2014. Microbial contamination of domiciliary nebulisers and 
clinical implications in chronic obstructive pulmonary disease. BMJ Open Respiratory 
Research 1. 
Jayaraman, S., Song, Y., Vetrivel, L., Shankar, L., Verkman, A.S., 2001. Noninvasive in vivo 
fluorescence measurement of airway-surface liquid depth, salt concentration, and pH. J. Clin. 
Invest. 107, 317-324. 
Jin, T.H., Tsao, E., Goudsmit, J., Dheenadhaylan, V., Sadoff, J., 2010. Stabilizing 
formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine 
(AERAS-402). Vaccine 28, 4369-4375. 
Kibbe, A.H., Association, A.P., 2000. Handbook of Pharmaceutical Excipients. American 
Pharmaceutical Association. 
Klingler, C., Muller, B.W., Steckel, H., 2009. Insulin-micro- and nanoparticles for pulmonary 
delivery. Int. J. Pharm. 377, 173-179. 
Křepela, E., Procházka, J., Mynaříková, H., Kárová, B., Polák, J., Čermák, J., Roubková, H., 
1995. Multiple forms of cathepsin b in human lung cancer. Int. J. Cancer 61, 44-53. 
 30 
Kurinomaru, T., Tomita, S., Hagihara, Y., Shiraki, K., 2014. Enzyme Hyperactivation System 
Based on a Complementary Charged Pair of Polyelectrolytes and Substrates. Langmuir 30, 
3826-3831. 
Kurinomaru, T., Tomita, S., Kudo, S., Ganguli, S., Nagasaki, Y., Shiraki, K., 2012. Improved 
Complementary Polymer Pair System: Switching for Enzyme Activity by PEGylated 
Polymers. Langmuir 28, 4334-4338. 
Labiris, N.R., Dolovich, M.B., 2003. Pulmonary drug delivery. Part II: The role of inhalant 
delivery devices and drug formulations in therapeutic effectiveness of aerosolized 
medications. Br. J. Clin. Pharmacol. 56, 600-612. 
Lechuga-Ballesteros, D., Charan, C., Stults, C.L., Stevenson, C.L., Miller, D.P., Vehring, R., 
Tep, V., Kuo, M.C., 2008. Trileucine improves aerosol performance and stability of spray-
dried powders for inhalation. J. Pharm. Sci. 97, 287-302. 
Li, H.Y., Neill, H., Innocent, R., Seville, P., Williamson, I., Birchall, J.C., 2003. Enhanced 
dispersibility and deposition of spray-dried powders for pulmonary gene therapy. J. Drug 
Target. 11, 425-432. 
Li, H.Y., Seville, P.C., Williamson, I.J., Birchall, J.C., 2005. The use of amino acids to 
enhance the aerosolisation of spray-dried powders for pulmonary gene therapy. J. Gene Med. 
7, 343-353. 
Littringer, E.M., Mescher, A., Eckhard, S., Schröttner, H., Langes, C., Fries, M., Griesser, U., 
Walzel, P., Urbanetz, N.A., 2012a. Spray Drying of Mannitol as a Drug Carrier—The Impact 
of Process Parameters on Product Properties. Drying Technol. 30, 114-124. 
Littringer, E.M., Mescher, A., Schroettner, H., Achelis, L., Walzel, P., Urbanetz, N.A., 
2012b. Spray dried mannitol carrier particles with tailored surface properties--the influence of 
carrier surface roughness and shape. Eur. J. Pharm. Biopharm. 82, 194-204. 
Lucas, P., Anderson, K., Potter, U.J., Staniforth, J.N., 1999. Enhancement of Small Particle 
Size Dry Powder Aerosol Formulations using an Ultra Low Density Additive. Pharm. Res. 
16, 1643-1647. 
Maa, Y.F., Costantino, H.R., Nguyen, P.A., Hsu, C.C., 1997. The effect of operating and 
formulation variables on the morphology of spray-dried protein particles. Pharm. Dev. 
Technol. 2, 213-223. 
Malik, D.K., Baboota, S., Ahuja, A., Hasan, S., Ali, J., 2007. Recent advances in protein and 
peptide drug delivery systems. Curr Drug Deliv 4, 141-151. 
Maltesen, M.J., Bjerregaard, S., Hovgaard, L., Havelund, S., van de Weert, M., 2008. Quality 
by design - Spray drying of insulin intended for inhalation. Eur. J. Pharm. Biopharm. 70, 828-
838. 
Masuda, T., Ide, N., Kitabatake, N., 2005. Structure–Sweetness Relationship in Egg White 
Lysozyme: Role of Lysine and Arginine Residues on the Elicitation of Lysozyme Sweetness. 
Chem. Senses 30, 667-681. 
Maury, M., Murphy, K., Kumar, S., Mauerer, A., Lee, G., 2005a. Spray-drying of proteins: 
effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an 
immunoglobulin G. Eur. J. Pharm. Biopharm. 59, 251-261. 
Maury, M., Murphy, K., Kumar, S., Shi, L., Lee, G., 2005b. Effects of process variables on 
the powder yield of spray-dried trehalose on a laboratory spray-dryer. Eur. J. Pharm. 
Biopharm. 59, 565-573. 
 31 
Melancon, M.P., Wang, W., Wang, Y., Shao, R., Ji, X., Gelovani, J.G., Li, C., 2007. A Novel 
Method for Imaging In Vivo Degradation of Poly(L-Glutamic Acid), a Biodegradable Drug 
Carrier. Pharm. Res. 24, 1217-1224. 
Nieto-Orellana, A., Di Antonio, M., Conte, C., Falcone, F.H., Bosquillon, C., Childerhouse, 
N., Mantovani, G., Stolnik, S., 2017. Effect of polymer topology on non-covalent polymer-
protein complexation: miktoarm versus linear mPEG-poly(glutamic acid) copolymers. 
Polymer Chemistry 8, 2210-2220. 
Niven, R.W., 1995. Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug 
Carrier Syst. 12, 151-231. 
Nyambura, B.K., Kellaway, I.W., Taylor, K.M.G., 2009. Insulin nanoparticles: Stability and 
aerosolization from pressurized metered dose inhalers. Int. J. Pharm. 375, 114-122. 
Ogain, O.N., Li, J., Tajber, L., Corrigan, O.I., Healy, A.M., 2011. Particle engineering of 
materials for oral inhalation by dry powder inhalers. I-Particles of sugar excipients (trehalose 
and raffinose) for protein delivery. Int. J. Pharm. 405, 23-35. 
Ohtake, S., Schebor, C., Palecek, S.P., de Pablo, J.J., 2004. Effect of pH, counter ion, and 
phosphate concentration on the glass transition temperature of freeze-dried sugar-phosphate 
mixtures. Pharm. Res. 21, 1615-1621. 
Okudela, K., Mitsui, H., Woo, T., Arai, H., Suzuki, T., Matsumura, M., Kojima, Y., Umeda, 
S., Tateishi, Y., Masuda, M., Ohashi, K., 2016. Alterations in cathepsin L expression in lung 
cancers. Pathol. Int. 66, 386-392. 
Olsen, J.V., Ong, S.-E., Mann, M., 2004. Trypsin Cleaves Exclusively C-terminal to Arginine 
and Lysine Residues. Mol. Cell. Proteomics 3, 608-614. 
Ong, H.X., Traini, D., Ballerin, G., Morgan, L., Buddle, L., Scalia, S., Young, P.M., 2014. 
Combined Inhaled Salbutamol and Mannitol Therapy for Mucus Hyper-secretion in 
Pulmonary Diseases. The AAPS Journal 16, 269-280. 
Orlowski, M., Orlowski, J., Lesser, M., Kilburn, K.H., 1981. Proteolytic enzymes in 
bronchopulmonary lavage fluids: cathepsin B-like activity and prolyl endopeptidase. J. Lab. 
Clin. Med. 97, 467-476. 
Palazzo, F., Giovagnoli, S., Schoubben, A., Blasi, P., Rossi, C., Ricci, M., 2013. 
Development of a spray-drying method for the formulation of respirable microparticles 
containing ofloxacin-palladium complex. Int. J. Pharm. 440, 273-282. 
Park, S.-H., Kwon, J.-H., Lim, S.-H., Park, H.W., Kim, C.-W., 2007. Characterization of 
human insulin microcrystals and their absorption enhancement by protease inhibitors in rat 
lungs. Int. J. Pharm. 339, 205-212. 
Pilcer, G., Wauthoz, N., Amighi, K., 2012. Lactose characteristics and the generation of the 
aerosol. Adv Drug Deliv Rev 64, 233-256. 
Roe, K.D., Labuza, T.P., 2005. Glass Transition and Crystallization of Amorphous 
Trehalose-sucrose Mixtures. Int. J. Food Prop. 8, 559-574. 
Scheuch, G., Kohlhaeufl, M.J., Brand, P., Siekmeier, R., 2006. Clinical perspectives on 
pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 58, 996-1008. 
Schüle, S., Frieß, W., Bechtold-Peters, K., Garidel, P., 2007. Conformational analysis of 
protein secondary structure during spray-drying of antibody/mannitol formulations. Eur. J. 
Pharm. Biopharm. 65, 1-9. 
 32 
Shiga, H., Joreau, H., Neoh, L.T., Furuta, T., Yoshii, H., 2014. Encapsulation of Alcohol 
Dehydrogenase in Mannitol by Spray Drying. Pharmaceutics 6. 
Sivadas, N., O'Rourke, D., Tobin, A., Buckley, V., Ramtoola, Z., Kelly, J.G., Hickey, A.J., 
Cryan, S.A., 2008. A comparative study of a range of polymeric microspheres as potential 
carriers for the inhalation of proteins. Int. J. Pharm. 358, 159-167. 
Soppimath, K.S., Aminabhavi, T.M., Kulkarni, A.R., Rudzinski, W.E., 2001. Biodegradable 
polymeric nanoparticles as drug delivery devices. J. Control. Release 70, 1-20. 
Stratford, R.E., Lee, V.H.L., 1986. Aminopeptidase activity in homogenates of various 
absorptive mucosae m the albino rabbit: implications in peptide delivery. Int. J. Pharm. 30, 
73-82. 
Sung, J.C., Pulliam, B.L., Edwards, D.A., 2007. Nanoparticles for drug delivery to the lungs. 
Trends Biotechnol. 25, 563-570. 
Takada, A., Nail, S.L., Yonese, M., 2009. Influence of ethanol on physical state of freeze-
dried mannitol. Pharm. Res. 26, 1112-1120. 
Tomita, S., Ito, L., Yamaguchi, H., Konishi, G.-i., Nagasaki, Y., Shiraki, K., 2010. Enzyme 
switch by complementary polymer pair system (CPPS). Soft Matter 6, 5320-5326. 
Torrado, S., Torrado, S., 2002. Characterization of physical state of mannitol after freeze-
drying: effect of acetylsalicylic acid as a second crystalline cosolute. Chem. Pharm. Bull. 
(Tokyo) 50, 567-570. 
Tzannis, S.T., Prestrelski, S.J., 1999. Activity–stability considerations of trypsinogen during 
spray drying: Effects of sucrose. J. Pharm. Sci. 88, 351-359. 
Umashankar, M.S., Sachdeva, R.K., Gulati, M., 2010. Aquasomes: a promising carrier for 
peptides and protein delivery. Nanomedicine 6, 419-426. 
Vehring, R., 2008. Pharmaceutical Particle Engineering via Spray Drying. Pharm. Res. 25, 
999-1022. 
Wall, D.A., Lanutti, A.T., 1993. High levels of exopeptidase activity are present in rat and 
canine bronchoalveolar lavage fluid. Int. J. Pharm. 97, 171-181. 
Weers, J.G., Tarara, T.E., Clark, A.R., 2007. Design of fine particles for pulmonary drug 
delivery. Expert Opin Drug Deliv 4, 297-313. 
Werle, B., Ebert, W., Klein, W., Spiess, E., 1994. Cathepsin B in tumors, normal tissue and 
isolated cells from the human lung. Anticancer Res. 14, 1169-1176. 
Wetter, L.R., Deutsch, H.F., 1951. Immunological studies on egg white proteins. IV. 
Immunochemical and physical studies of lysozyme. J. Biol. Chem. 192, 237-242. 
You, Y., Zhao, M., Liu, G., Tang, X., 2007. Physical characteristics and aerosolization 
performance of insulin dry powders for inhalation prepared by a spray drying method. J. 
Pharm. Pharmacol. 59, 927-934. 
 
